COMPANY PROFILE

Lexeo Therapeutics

Revolutionizes human health therapeutics by applying the science of gene therapy to treat and cure some of the world’s most devastating genetic and acquired diseases

New York City, United StatesFounded 2018Biotech & Life Sciences

Valuation $229M Market cap · 2026

About Lexeo Therapeutics

LEXEO Therapeutics, founded in 2018, is a biotechnology company based in New York that specializes in gene therapy. The company focuses on developing treatments for both common and rare diseases, particularly in the areas of cardiac and neurological conditions. Leveraging a strong research foundation from Weill Cornell Department of Genetic Medicine, LEXEO aims to address unmet medical needs through pioneering genetic medicine. The company serves patients who suffer from genetic disorders and collaborates with clinicians and researchers to bring advanced therapies to market. LEXEO operates in the biotech sector, targeting healthcare providers, medical institutions, and patients as its primary clients. The business model is centered around research and development, clinical trials, and eventual commercialization of gene therapies. Revenue is generated through partnerships, grants, and future sales of approved therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2018
Headquarters: New York City, United States
Listing: IPO 2023
Employees: 95
Open positions: 14
Dealroom signal: 49.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Disease, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Jul 2021
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
PRIVATE PLACEMENT NON VCOther financing	Oct 2025	$10M	—	Balyasny Asset Management	↗
POST IPO EQUITYOther financing	Oct 2025	$143M	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$0	—	−$109M	—
2025	$0	—	−$101M	—
2024	$0	—	−$96M	—
2023	$0	-100%	−$64M	—
2022	$654K	-60.5%	−$58M	-8874.8%
2021	$1.7M	+219.6%	−$51M	-3054.3%
2020	$518K	—	−$4.6M	-884%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Lexeo Therapeutics website traffic

Latest recorded traffic for Lexeo Therapeutics is 7.6K monthly website visits, down 17.4% over the last three months. Lexeo Therapeutics's team grew 13.1% over the past year.

Latest monthly visits7.6K 3-month web change-17.4% 1-year team growth+13.1%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Director, AI and Data Science (Drug Discovery and R&D Enablement)New York, New York, United States, Northern America, Americas · Data Science & Engineering · Jul 24, 2026 Senior Scientist, Process Development (AAV)New York, New York, United States, Northern America, Americas · Other · Jul 24, 2026 Associate Director, Quality Systems and ComplianceNew York, New York, United States, Northern America, Americas · Human Resources · Jul 24, 2026 Senior Manager/Associate Director, MSAT/Process Characterization and Validation Readiness (AAV)New York, NY · Full-Stack Development · Jul 16, 2026 Senior Scientist, Process Development (AAV)New York, NY · Other · Jul 16, 2026 Associate Director, Quality Systems and ComplianceNew York, NY · Human Resources · Jul 11, 2026 Vice President, Medical AffairsNew York, New York, United States, Northern America, Americas · Other · Jun 15, 2026 Director/Sr. Director, Capital Markets FinanceNew York, NY · Finance · Feb 24, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
APApcinteXAnticoagulant inhibitor treatment for all types of haemophilia	London, United Kingdom	Acquired
CTConfo TherapeuticsDrug discovery platform targeting previously inaccessible GPCRs	Ghent, Belgium	Operational
MIMironidSmall molecule therapeutics for hereditary kidney disease	Glasgow, United Kingdom	Operational
LPLexicon PharmaceuticalsBiopharmaceutical company that has harnessed the power of genetics for drug discovery	The Woodlands, United States	Operational
ERErydelRed-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases	Bresso, Italy	Acquired
SISiSafAdvancing RNA Therapeutics	Guildford, United Kingdom	Operational
SPSanthera PharmaceuticalsSanthera Pharmaceuticals is a Swiss specialty company dedicated to developing innovative medicines for rare neuromuscular diseases with significant unmet medical needs	Pratteln, Switzerland	Operational